Disruptive innovation in rheumatology: new networks of global public-private partnerships are needed to take advantage of scientific progress

Affiliations

• ¹ Rheumatology, Leiden University Medical Center, Leiden, Netherlands t.w.j.huizinga@lumc.nl.
• ² Rheumatology, University of Colorado School of Medicine, Aurora, Denver, Colorado, USA.
• ³ Division of Allergy, Immunology, and Rheumatology, Department of Medicine, University of Rochester School of Medicine, Rochester, New York, USA.
• ⁴ Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Massachusetts, USA.
• ⁵ Department of Rheumatology, University of Birmingham, Birmingham, UK.
• ⁶ Rheumatology, The Hospital for Special Surgery, New York, New York, USA.
• ⁷ Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada.
• ⁸ Department of Immunology and Inflammation, Bristol Myers Squibb Co. Research and Development, Princeton, New Jersey, USA.
• ⁹ Division of Rheumatology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
• ¹⁰ Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.
• ¹¹ Department of Rheumatology, Pfizer Global Pharmaceuticals, New York, New York, USA.
• ¹² Foundation for the National Institutes of Health, Bethesda, Maryland, USA.
• ¹³ Immunology and Inflammation Therapeutic Research Area Sanofi US, Sanofi Genzyme, Cambridge, Massachusetts, USA.
• ¹⁴ Experimental Medicine and Rheumatology, William Harvey Research Institute, London, UK.
• ¹⁵ Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, UK.
• ¹⁶ Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
• ¹⁷ Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
• ¹⁸ Rheumatology, Karolinska Institutet, Stockholm, Sweden.